. . . . . . . . . . . . . . . . . . . . . . . . . . "74191-85-8"@en . . "approved"@en . . . "Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α₁-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α₁-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland."@en . . . . . . . . . . . . . . . "Humans and other mammals"@en . . "98%"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Avoid natural licorice."@en . . . . . . . . . . "Avoid alcohol."@en . . . . . . . . . . . "Doxazosine"@en . . . "22 hours"@en . . . . . "Doxazosin"@en . . . . . "Doxazosin"@en . "Doxazosina"@en . . "K. S. Keshava Murthy, Gamini Weeratunga, Tianhao Zhou, Bhaskar Reddy Guntoori, \"Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tiodazosin and related antihypertensive medicines.\" U.S. Patent US5919931, issued September, 1986."@en . . . "Doxazosin mesylate"@en . . "# Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12461301"@en . . . . . "For treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH."@en . . . . . . "Doxazosin mesilate"@en . " "@en . . "Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation."@en . . . . . . "Symptoms of overdose include hypotension. Oral LD₅₀ is greater than 1000 mg/kg in mice and rats."@en . . . "Take without regard to meals."@en . . . . "1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin"@en . . . . . "Doxazosinum"@en . . . "1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin"@en . "65%"@en . . "On average only 4.8% of the dose was excreted as unchanged drug in the feces and only a trace of the total radioactivity in the urine was attributed to unchanged drug."@en . .